Premier Alternatives

Bioxodes

Gosselies, Belgium · Founded 2010 · Privately Held (backing)

Operator of a clinical-stage biopharmaceutical company intended to prevent and treat thrombotic and inflammatory diseases. Bioxodes is based in Gosselies, Belgium and was founded in 2010. Its last reported valuation was $116 million in Feb 2025. It has raised $39.1 million.

Last reported valuation
$115.5M
Oct 2026
Priced at
—
Total raised
$39.1M
Last round
—

Bioxodes key facts

as of Oct 2026
  • Operator of a clinical-stage biopharmaceutical company intended to prevent and treat thrombotic and inflammatory diseases.
  • Bioxodes is valued at approximately $115.5M as of Oct 2026 (last reported valuation).
  • It has raised $39.1M; the latest was Later Stage VC ($82.9M) in Feb 2025.
  • Notable investors include European Regional Development Fund (Brandenburg), SambrInvest, Société Fédérale de Participations et d'Investissement, Federal Holding and Investment Company (Brussels), Université Libre de Bruxelles — 12 tracked in total.
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$115.5M

Bioxodes's last reported valuation, Feb 2025. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Bioxodes with a free account
  • ·The complete investor list: 12 names
  • ·Watch Bioxodes: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Bioxodes funding rounds

No rounds on record

No funding rounds for Bioxodes are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Bioxodes valuation

Bioxodes's last reported valuation was $116 million in Feb 2025. No priced round, secondary trade or fund mark has surfaced since.

Bioxodes investors

12 investors are on record for Bioxodes, including European Regional Development Fund (Brandenburg), SambrInvest, Société Fédérale de Participations et d'Investissement and Federal Holding and Investment Company (Brussels).

About Bioxodes

Operator of a clinical-stage biopharmaceutical company intended to prevent and treat thrombotic and inflammatory diseases. The company's platform prevents blood clot formation without increasing the risk of further bleeding, the way anticoagulants inhibit the activation of neutrophils, a type of white blood cell that often acts as the first responders of the inflammatory system, offers a balance between antithrombotic benefits and hemorrhagic side effects, enabling healthcare providers to prevent thrombosis.

Sector
Healthcare
HQ
Gosselies, Belgium
Founded
2010
Employees
8
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.